This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ertugliflozin and Sitagliptin Fixed Dose Combo

Merck & Co., Inc.

Drug Names(s): Ertugliflozin and Sitagliptin, ertugliflozin and Januvia, Ertugliflozin/Sitagliptin

Description: Merck is developing a combination of Ertugliflozin and Sitagliptin.

Deal Structure: Pfizer and Merck
In April 2013, Merck and Pfizer entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizers ertugliflozin (PF-04971729) being evaluated for the treatment of type 2 diabetes. Under the terms of the agreement, Merck, through a subsidiary, and Pfizer will collaborate on the clinical development and commercialization of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and JANUVIA (sitagliptin) tablets. Merck will continue to retain the rights to its existing portfolio of sitagliptin-containing products. Pfizer has received an upfront payment and milestones of $60 million and will be eligible for additional payments associated with the achievement of pre-specified future clinical, regulatory and commercial milestones. Merck and Pfizer will share potential revenues and certain costs on a 60/40 percent basis.

Partners: Pfizer Inc.


Ertugliflozin and Sitagliptin Fixed Dose Combo News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug